Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 9, Pages 1872-1881
Publisher
Springer Nature
Online
2016-12-26
DOI
10.1038/leu.2016.382
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
- (2016) K. Bojarczuk et al. BLOOD
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
- (2016) Qingshan Yang et al. CLINICAL CANCER RESEARCH
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212
- (2015) Simona Tavolaro et al. GENES CHROMOSOMES & CANCER
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
- (2014) U. Rozovski et al. BLOOD
- The future of autologous stem cell transplantation in myeloma
- (2014) F. van Rhee et al. BLOOD
- Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
- (2014) S. Krysov et al. BLOOD
- Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
- (2014) V. Patel et al. BLOOD
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
- (2014) D. Wodarz et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- (2014) S E M Herman et al. LEUKEMIA
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia
- (2013) Viralkumar Patel et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
- (2013) Jan A. Burger et al. SEMINARS IN CANCER BIOLOGY
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1
- (2012) Christine E. Gilling et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia
- (2011) A. Paterson et al. BLOOD
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- The role of Bcl-2 family proteins in chronic lymphocytic leukaemia
- (2010) Andrea G.S. Buggins et al. LEUKEMIA RESEARCH
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation
- (2009) L. A. O'Reilly et al. JOURNAL OF IMMUNOLOGY
- Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
- (2009) M Plander et al. LEUKEMIA
- Chronic lymphocytic leukaemia: a short overview
- (2008) E. Montserrat et al. ANNALS OF ONCOLOGY
- BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells
- (2008) A. Guarini et al. BLOOD
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
- (2008) J. A. Burger et al. BLOOD
- Direct multiplexed measurement of gene expression with color-coded probe pairs
- (2008) Gary K Geiss et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started